Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. director Sara R. May reported a new equity award in the form of stock options. On December 16, 2025, she was granted a stock option covering 25,000 common shares of Medicus Pharma.
The option has an exercise price of $1.80 per share and is scheduled to vest quarterly in four equal installments over one year, giving her rights to the shares gradually rather than all at once. The option is currently shown as directly owned and is scheduled to expire on December 16, 2030 if not exercised.
Medicus Pharma Ltd. reported that director Patrick J. Mahaffy received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of $1.8 per share. It is scheduled to vest quarterly in four equal installments over one year, meaning the award becomes fully vested after that period. The option expires on December 16, 2030, providing a five-year window from grant date for potential exercise.
Medicus Pharma Ltd. reported an insider equity grant involving director Larry Kaiser. On December 16, 2025, he received a stock option to purchase 25,000 common shares of Medicus Pharma at an exercise price of $1.80 per share. The option is scheduled to vest quarterly in four equal installments over one year and is listed as directly owned. According to the filing, the option expires on December 16, 2030, and following this transaction Kaiser beneficially owns 25,000 derivative securities in the form of these options.
Medicus Pharma Ltd. director Barry Fishman reported receiving a stock option grant covering 25,000 common shares on 12/16/2025. The stock option has an exercise price of $1.8 per share and is scheduled to vest quarterly in four equal installments over one year from the grant date. The option expires on 12/16/2030. Following this grant, Barry Fishman beneficially owns 25,000 derivative securities in the form of these options, held directly.
Medicus Pharma Ltd. reported that director Robert J. Ciaruffoli received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of $1.8 per share and was granted at no upfront cost.
The option is scheduled to vest quarterly in four equal installments over one year and expires on December 16, 2030. After this grant, he beneficially owns 25,000 stock options, held directly.
Medicus Pharma Ltd. reported that its Chief Scientific Officer, Edward J. Brennan, received a stock option grant covering 50,000 common shares on December 16, 2025. The options have an exercise price of $1.8 per share and expire on December 16, 2030.
The award is scheduled to vest quarterly in four equal installments over one year, and 50,000 derivative securities are listed as beneficially owned directly following the grant.
Medicus Pharma Ltd. reported an equity award for its President and CFO, Carolyn F. Bonner. On December 16, 2025, she received a stock option grant covering 75,000 common shares at an exercise price of $1.8 per share. These options are scheduled to vest quarterly in four equal installments over one year, meaning portions of the grant become exercisable every quarter during that period.
After this grant, she held 75,000 derivative securities directly, all tied to the company’s common shares. This type of award is a common form of equity-based compensation that links an executive’s potential future gains to the company’s share performance.
Medicus Pharma Ltd. (MDCX) reported an equity award to its Chief Executive Officer and director, Raza Bokhari. On December 16, 2025, he received a stock option covering 125,000 common shares with an exercise price of $1.8 per share and an expiration date of December 16, 2030. The option is scheduled to vest quarterly in four equal installments over one year, meaning the award becomes fully vested after that period if service conditions are met. Following the grant, 125,000 derivative securities are shown as beneficially owned with direct ownership.
Medicus Pharma Ltd. reported a new stock option grant to a director. On December 16, 2025, the director received a stock option to buy 25,000 common shares of Medicus Pharma at an exercise price of $1.8 per share, expiring on December 16, 2030.
The option is scheduled to vest quarterly in four equal installments over one year, aligning the director’s potential equity ownership with short-term company performance. Following this grant, the director beneficially owns 25,000 derivative securities, held as a direct ownership position.
Medicus Pharma Ltd. filed a prospectus supplement covering the resale of up to 2,680,000 common shares tied to previously issued warrants. The supplement adds information from a new current report about a warrant inducement agreement and recent equity sales.
On December 5, 2025 the company agreed with an accredited institutional holder to amend existing warrants for up to 2,680,000 common shares to an exercise price of $1.92 per share. In return, the holder will receive new unregistered warrants for up to 4,020,000 additional common shares at $2.00 per share, expiring on June 5, 2031, with one series allowing the company to force exercise if the 10‑day average VWAP reaches $10.00. Gross proceeds from the exercise of the existing warrants are expected to be approximately $5.1 million, before expenses and a 6.0% cash fee to Maxim Group LLC.
The company plans to register the resale of the shares underlying the new warrants by filing a new registration statement within 60 days and keeping it effective until the original holder can sell under Rule 144 without limits. Separately, under its Standby Equity Purchase Agreement with Yorkville, Medicus Pharma sold 680,893 common shares for aggregate consideration of $1,500,905 and used part of the net proceeds to prepay a portion of an outstanding debenture. Its common shares trade on the Nasdaq Capital Market under the symbol MDCX, with a last reported price of $2.05 on December 5, 2025.